Barbell Medicine Podcast cover image

Barbell Medicine Podcast

Episode #231: BMI Controversy and New Drug Breakthroughs

Jun 28, 2023
01:15:01

Podcast summary created with Snipd AI

Quick takeaways

  • Riptatritide shows remarkable weight loss in obesity treatment, surpassing standard medications.
  • Kaggersema dual medication offers significant reductions in A1C levels and weight loss for glucose management.

Deep dives

Riptatritide: Promising Drug for Obesity Treatment

A new drug, Riptatritide, is a glucagon, GIP, GLP1 triple agonist being studied for obesity treatment. In a phase two trial, participants with obesity saw substantial weight loss, with the highest dose group achieving an average weight loss of 24% over 48 weeks, exceeding previously studied medications. Participants at all doses experienced weight loss, and at the highest dose, average absolute weight loss was 58 pounds, leading to improvements in blood lipid profiles and liver fat reduction.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner